Table 3 Emerging or attempted therapies for nAMD

Abicipar pegol

Allergan

DARPin

IVT

III, terminated

NCT02462928,

NCT02462486

Conbercept/Lumitin

Chengdu Kang Hong Biotech

Fusion protein “trap”

IVT

III, terminated

NCT03577899, NCT03630952

PAN-90806

PanOptica

Small molecule

Eye drops

I/II

NCT03479372

RGX-314

RegenxBio

AAV8 gene therapy delivering anti-VEGF Fab

Subretinal

II

NCT04832724

ADVM-022

Adverum

AAV7m8 gene therapy delivering aflibercept

IVT

I

NCT03748784, NCT04645212

KSI-301

Kodiak

Antibody biopolymer conjugate

IVT

IIb/III

NCT04049266

OPT-302

Opthea

Fusion protein “trap”

IVT

III

NCT04757610, NCT04757636

EYP-1901

Eyepoint

Small molecule in Durasert

IVT

I

NCT04747197

Pluripotent stem-cells

London Project to Cure Blindness

hESC-derived RPE monolayer

Transplantation

I

NCT01691261

Pluripotent stem-cells

Highway Program for Realization of Regenerative Medicine

Autologous iPSC-derived RPE cell sheet

Transplantation

UMIN000011929

Heparin-binding VEGFR1 variants

University of California San Diego

Fc fusion proteins

IVT

N/A

OXU-005

Oxular

Small molecule in Oxuspheres

IVT

N/A

Brivanib

Nantong University

Small molecule

IVT, gavage

N/A

AGX51

Memorial Sloan Kettering Cancer Center

Small molecule

IVT

N/A

THR-687

Oxurion

integrin receptor antagonist

IVT

N/A

Vasotide

Beth Israel Deaconess Medical Center

peptidomimetic

Eye drops

N/A

BT2

UNSW

Small molecule

IVT

N/A

Sunitinib

Johns Hopkins University

Small molecule

IVT

N/A

APX2009, APX2014

Indiana University

Small molecule

Systemic

N/A